These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 38048777)
1. The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism. Sun Y; Zhang L; Jiang Z Basic Clin Pharmacol Toxicol; 2024 Mar; 134(3):315-324. PubMed ID: 38048777 [TBL] [Abstract][Full Text] [Related]
2. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases. Gallucci GM; Hayes CM; Boyer JL; Barbier O; Assis DN; Ghonem NS Cells; 2024 Aug; 13(15):. PubMed ID: 39120326 [TBL] [Abstract][Full Text] [Related]
3. New therapies target the toxic consequences of cholestatic liver disease. Jansen PLM Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470 [TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. Barbier O; Duran-Sandoval D; Pineda-Torra I; Kosykh V; Fruchart JC; Staels B J Biol Chem; 2003 Aug; 278(35):32852-60. PubMed ID: 12810707 [TBL] [Abstract][Full Text] [Related]
6. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor. Li T; Xu L; Zheng R; Wang X; Li L; Ji H; Hu Q Phytomedicine; 2020 Mar; 68():153153. PubMed ID: 32018210 [TBL] [Abstract][Full Text] [Related]
7. Novel and emerging therapies for cholestatic liver diseases. Goldstein J; Levy C Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112 [TBL] [Abstract][Full Text] [Related]
8. Nuclear receptors as drug targets in cholestatic liver diseases. Halilbasic E; Baghdasaryan A; Trauner M Clin Liver Dis; 2013 May; 17(2):161-89. PubMed ID: 23540496 [TBL] [Abstract][Full Text] [Related]
9. Nuclear Receptor Regulation of Aquaglyceroporins in Metabolic Organs. Tardelli M; Claudel T; Bruschi FV; Trauner M Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914059 [TBL] [Abstract][Full Text] [Related]
10. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model. Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286 [TBL] [Abstract][Full Text] [Related]
11. Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism. Duparc T; Plovier H; Marrachelli VG; Van Hul M; Essaghir A; Ståhlman M; Matamoros S; Geurts L; Pardo-Tendero MM; Druart C; Delzenne NM; Demoulin JB; van der Merwe SW; van Pelt J; Bäckhed F; Monleon D; Everard A; Cani PD Gut; 2017 Apr; 66(4):620-632. PubMed ID: 27196572 [TBL] [Abstract][Full Text] [Related]
12. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Zollner G; Trauner M Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988 [TBL] [Abstract][Full Text] [Related]
13. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Ide T; Shimano H; Yoshikawa T; Yahagi N; Amemiya-Kudo M; Matsuzaka T; Nakakuki M; Yatoh S; Iizuka Y; Tomita S; Ohashi K; Takahashi A; Sone H; Gotoda T; Osuga J; Ishibashi S; Yamada N Mol Endocrinol; 2003 Jul; 17(7):1255-67. PubMed ID: 12730332 [TBL] [Abstract][Full Text] [Related]
14. Targeting nuclear bile acid receptors for liver disease. Trauner M; Baghdasaryan A; Claudel T; Fickert P; Halilbasic E; Moustafa T; Zollner G Dig Dis; 2011; 29(1):98-102. PubMed ID: 21691114 [TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism. Latruffe N; Vamecq J Biochimie; 1997; 79(2-3):81-94. PubMed ID: 9209701 [TBL] [Abstract][Full Text] [Related]
16. The role of the enterohepatic circulation of bile salts and nuclear hormone receptors in the regulation of cholesterol homeostasis: Bile salts as ligands for nuclear hormone receptors. Redinger RN Can J Gastroenterol; 2003 Apr; 17(4):265-71. PubMed ID: 12704471 [TBL] [Abstract][Full Text] [Related]
17. Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases. Latruffe N; Cherkaoui Malki M; Nicolas-Frances V; Clemencet MC; Jannin B; Berlot JP Biochem Pharmacol; 2000 Oct; 60(8):1027-32. PubMed ID: 11007938 [TBL] [Abstract][Full Text] [Related]
18. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255 [TBL] [Abstract][Full Text] [Related]
19. Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Kidani Y; Bensinger SJ Immunol Rev; 2012 Sep; 249(1):72-83. PubMed ID: 22889216 [TBL] [Abstract][Full Text] [Related]
20. Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells. Panzenboeck U; Kratzer I; Sovic A; Wintersperger A; Bernhart E; Hammer A; Malle E; Sattler W Int J Biochem Cell Biol; 2006; 38(8):1314-29. PubMed ID: 16530456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]